The global aseptic fill finish manufacturing market size was estimated to be $5.4 billion in 2023. The use of hydrogen peroxide bio-decontamination is critical to the equipment used in these processes and has become the standard requirement for use. The use of enzyme indicators to ensure that these processes run as efficiently and accurately as possible supports this need as well as developing a standard methodology for their use. Protak Scientific have developed this enzyme indicator technology in partnership with the UK Health Security Agency (UKHSA).
Katie Marshall is Protak Scientific’s Technical Director, responsible for areas including product design control and improvements, production, quality and validation, and the future product roadmap. She also has an externally facing role that includes customer support and training, case studies, publications, thought leadership, and regulatory guidance approaches. She recognises that, “I have always been the person responsible for technical project execution so to be able to fully grow into my role as Technical Director as the company grows, I need to develop and delegate to my current team (and future recruits) more effectively to execute.”
She also recognises that in a period of rapid change being able to support and train her team in Agile planning techniques will be instrumental to this. She recognises that the Shott Scale Up Accelerator can provide access to a mentor and coach to discuss ideas, unblock thinking, and discuss alternative solutions and this will be invaluable for her development. She also sees the benefit of gaining access to new networks that potentially offer alternative solutions and new contacts.
Protak Scientific’s five-year goal is for their technology to be globally recognised as the validation tool for the bio-decontamination activities within the pharmaceutical manufacturing space and beyond. To achieve this, their growth into these sectors within the next 12 months will be key.
